Literature DB >> 8486972

Role of superantigens in human disease.

P M Schlievert1.   

Abstract

Superantigens include bacterial products (mainly of streptococci and staphylococci) that stimulate T cells to proliferate nonspecifically through interaction with class II major histocompatibility complex products on antigen-presenting cells and then with variable regions on the beta chain of the T cell receptor complex. They include pyrogenic toxins (streptococcal scarlet fever toxins of serotypes A, B, and C, toxic shock syndrome toxin 1, and staphylococcal enterotoxin serotypes A, B, Cn, D, E, and G), streptococcal M protein, staphylococcal exfoliative toxin, and recently identified pyrogenic toxins made by groups B, C, F, and G streptococci and Streptococcus sanguis. Pyrogenic toxin superantigens cause acute toxic shock syndrome and are associated with toxic shock-like syndromes. Superantigens cause symptoms via release of immune cytokines. These proteins should be considered potential causes of illnesses such as rheumatic fever, arthritis, Kawasaki syndrome, atopic dermatitis, and guttate psoriasis because of their potent immune system-altering capacity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486972     DOI: 10.1093/infdis/167.5.997

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  82 in total

Review 1.  Immune response to staphylococcal superantigens.

Authors:  T Krakauer
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Multiplex PCR for detection of genes for Staphylococcus aureus enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance.

Authors:  M Mehrotra; G Wang; W M Johnson
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

3.  Coordinate suppression of superantigen-induced cytokine production and T-cell proliferation by a small nonpeptidic inhibitor of class II major histocompatibility complex and CD4 interaction.

Authors:  T Krakauer
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 4.  Group A Streptococcus: allelic variation, population genetics, and host-pathogen interactions.

Authors:  S D Reid; N P Hoe; L M Smoot; J M Musser
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIalpha.

Authors:  Heike I Krupka; Brent W Segelke; Robert G Ulrich; Sabine Ringhofer; Mark Knapp; Bernhard Rupp
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

6.  Nonsteroidal anti-inflammatory drugs and streptococcal toxic shock syndrome.

Authors:  Wolfram Schummer; Claudia Schummer
Journal:  Intensive Care Med       Date:  2002-08       Impact factor: 17.440

7.  Construction of a single-chain variable-fragment antibody against the superantigen Staphylococcal enterotoxin B.

Authors:  Pawan Kumar Singh; Ranu Agrawal; Dev Vrat Kamboj; Garima Gupta; M Boopathi; Ajay Kumar Goel; Lokendra Singh
Journal:  Appl Environ Microbiol       Date:  2010-10-15       Impact factor: 4.792

8.  Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome.

Authors:  Hatice Karauzum; Gang Chen; Laura Abaandou; Mahta Mahmoudieh; Atefeh R Boroun; Sergey Shulenin; V Sathya Devi; Eric Stavale; Kelly L Warfield; Larry Zeitlin; Chad J Roy; Sachdev S Sidhu; M Javad Aman
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

9.  Identification of staphylococcal enterotoxin B sequences important for induction of lymphocyte proliferation by using synthetic peptide fragments of the toxin.

Authors:  M Jett; R Neill; C Welch; T Boyle; E Bernton; D Hoover; G Lowell; R E Hunt; S Chatterjee; P Gemski
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).

Authors:  A Norrby-Teglund; D Newton; M Kotb; S E Holm; M Norgren
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.